Hematopoietic Stem Cell Transplantation in Thalassemia and Sickle Cell Disease. Unicenter Experience in a Multi-Ethnic Population.
2009

Hematopoietic Stem Cell Transplantation in Thalassemia and Sickle Cell Disease

Sample size: 145 publication Evidence: moderate

Author Information

Author(s): Marco Marziali, Antonella Isgrò, Javid Gaziev, Guido Lucarelli

Primary Institution: International Center for Transplantation in Thalassemia and Sickle Cell Anemia, Mediterranean Institute of Hematology, Rome- Italy

Hypothesis

Can hematopoietic stem cell transplantation (HSCT) effectively treat thalassemia and sickle cell disease in a multi-ethnic population?

Conclusion

HSCT is a viable and effective treatment for thalassemia and sickle cell disease, showing high survival rates in well-selected patients.

Supporting Evidence

  • HSCT has shown improved results over the last two decades due to better preventive strategies.
  • Patients with thalassemia and sickle cell anemia have a high risk of graft rejection due to sensitization.
  • Class 1 patients have a very high probability of cure with low morbidity and mortality.

Takeaway

Doctors can help kids with thalassemia and sickle cell disease by giving them special cells from a donor, which can make them healthy again.

Methodology

145 patients with thalassemia and sickle cell anemia received HSCT, with a focus on ethnic diversity and sensitization risks.

Potential Biases

Potential bias due to the ethnic diversity of the patient population and varying pre-transplant conditions.

Limitations

The study may not fully account for the long-term effects of HSCT and the specific challenges faced by highly sensitized patients.

Participant Demographics

Patients were ethnically heterogeneous from Mediterranean and Middle East countries, with a majority not regularly transfused.

Digital Object Identifier (DOI)

10.4084/MJHID.2009.027

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication